Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Cardiovascular Health This may help improve heart function and blood vessel repair
Y., Zin, M
The viscosity of the ER increases during ferroptosis, possibly due to aggregation of polyunsaturated fatty acids (PUFAs) and phospholipids, leading to hardening of the ER (Liu et al
It happens when your system is flooded with damaging molecules, known as free radicals, overwhelming your body's natural antioxidant defences
Absolute Contraindications Active malignancy Pregnancy and lactation Severe hypoglycemia disorders Known hypersensitivity to IGF-1 Active proliferative retinopathy Relative Contraindications Diabetes mellitus Renal impairment Cardiac impairment History of hyperplasia Family history of certain cancers Severe hepatic impairment Dosing & Administration Starting Dose 2050 mcg/day subcutaneously Begin at the lower end for sensitive patients Assess tolerance for 12 weeks before titration Therapeutic Range 50120 mcg/day for most indications Maximum dose: 200 mcg/day Individualize dosing based on response and tolerance Cycling Protocol 46 weeks on therapy 4 weeks off therapy Helps prevent receptor desensitization Supports long-term efficacy Administration Guidelines Hypoglycemia Prevention: Always administer IGF-1 LR3 with or shortly after carbohydrate-containing meals
Better yet: find good digestive enzymes
